Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients

BACKGROUND: Bevacizumab, an anti-VEGF monoclonal antibody, has recently emerged as a new option for severe forms of hereditary hemorrhagic telangiectasia (HHT). Its utilization in this orphan disease has rapidly spread despite the lack of randomized trials and international guidelines. The objective...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Guilhem, Alexandre, Fargeton, Anne-Emmanuelle, Simon, Anne-Claire, Duffau, Pierre, Harle, Jean-Robert, Lavigne, Christian, Carette, Marie-France, Bletry, Olivier, Kaminsky, Pierre, Leguy, Vanessa, Lerolle, Nathalie, Roux, Dominique, Lambert, Marc, Chinet, Thierry, Bonnet, Delphine, Dupuis-Girod, Sophie, Rivière, Sophie
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5708634/
https://ncbi.nlm.nih.gov/pubmed/29190827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0188943
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados